Vaxess Technologies, Inc.
Cambridge, US · Founded 2012 · Delaware corporation · 3 known investors
Founders & leadership
Vaxess Technologies, Inc. was founded in 2012 by Livio Valenti, Kathryn Kosuda, and Michael Schrader.
LV
Livio ValentiCo-founder
KK
Kathryn KosudaCo-founder
MS
Michael SchraderCo-founder
MD
Matthew DirckxExecutive
LT
Lynda TusseyExecutive
JS
John SpiridigliozziExecutive
WT
Weiner TilsnerExecutive
JK
Jonathan KlugeExecutive
RS
Rachel ShaExecutive
SH
Shuenn HoExecutive
Board
AD
Ann DeWittBoard director
PK
Investors · 3
Reported raises · per SEC filings
Form D private placements$136.9M disclosed across 10 rounds · 2016–2026
▶$57.3MraisedMar 2026 · 16 investors · BiotechnologyRule 506(b)
▶$57.3MraisedMar 2026 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Linda TusseyExecutive Officer
- Kathryn KousdaExecutive Officer, Director
- Livio ValentiExecutive Officer
- Ann DeWittDirector
- Fenel EloiDirector
- Peter KolchinskyDirector
- Rachel ShaExecutive Officer, Director
- Offering amount
- $83.5M
- Amount sold
- $57.3M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.9MraisedSep 2025 · 4 investors · BiotechnologyRule 506(b)
▶$7.9MraisedSep 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew DirckxExecutive Officer
- Jonathan KlugeExecutive Officer
- Ann DeWittDirector
- Fenel EloiDirector
- Rachel ShaExecutive Officer, Director
- Weiner TilsnerExecutive Officer
- Peter KolchinskyDirector
- Kathryn KosudaExecutive Officer, Director
- Lynda TusseyExecutive Officer
- John SpiridigliozziExecutive Officer
- Livio ValentiExecutive Officer
- Offering amount
- $10M
- Amount sold
- $7.9M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedFeb 2025 · 3 investors · BiotechnologyRule 506(b)
▶$8.4MraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ann DeWittDirector
- Matthew DirckxExecutive Officer
- Lynda TusseyExecutive Officer
- John SpiridigliozziExecutive Officer
- Weiner TilsnerExecutive Officer
- Livio ValentiExecutive Officer
- Peter KolchinskyDirector
- Jonathan KlugeExecutive Officer
- Kathryn KosudaExecutive Officer, Director
- Rachel ShaExecutive Officer, Director
- Fenel EloiDirector
- Offering amount
- $10M
- Amount sold
- $8.4M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.8MraisedMay 2024 · 6 investors · BiotechnologyRule 506(b)
▶$10.8MraisedMay 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lynda TusseyExecutive Officer
- Mario BarroDirector
- Kathryn KosudaExecutive Officer, Director
- Matthew DirckxExecutive Officer
- Ann DeWittDirector
- Weiner TilsnerExecutive Officer
- John SpiridigliozziExecutive Officer
- Rachel ShaExecutive Officer
- Fenel EloiDirector
- Jonathan KlugeExecutive Officer
- Livio ValentiExecutive Officer
- Offering amount
- $12M
- Amount sold
- $10.8M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.1MraisedJul 2023 · 4 investors · BiotechnologyRule 506(b)
▶$9.1MraisedJul 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mario BarroDirector
- Kathryn KosudaExecutive Officer, Director
- Livio ValentiExecutive Officer
- Jonathan KlugeExecutive Officer
- Fenel EloiDirector
- Ann DeWittDirector
- Michael SchraderExecutive Officer, Director
- Lynda TusseyExecutive Officer
- Offering amount
- $12.1M
- Amount sold
- $9.1M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedDec 2022 · 7 investors · BiotechnologyRule 506(b)
▶$35MraisedDec 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathryn KosudaExecutive Officer, Director
- Ann DeWittDirector
- Lynda TusseyExecutive Officer
- Jonathan KlugeExecutive Officer
- Michael SchraderExecutive Officer, Director
- Mario BarroDirector
- Fenel M. EloiDirector
- Livio ValentiExecutive Officer
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael SchraderExecutive Officer, Director
- Mario BarroDirector
- Ann DeWittDirector
- Livio ValentiExecutive Officer
- Jonathan KlugeExecutive Officer
- Kathryn KosudaExecutive Officer, Director
- Lynda TusseyExecutive Officer
- Fenel M. EloiDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2021 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Livio ValentiExecutive Officer
- Jonathan KlugeExecutive Officer
- Ted HibbenExecutive Officer
- Ann DeWittDirector
- Lynda TusseyExecutive Officer
- Michael SchraderExecutive Officer, Director
- Johannes FruehaufDirector
- Kathryn KosudaExecutive Officer, Director
- Purnanand SarmaDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded Vaxess Technologies, Inc.?
- Vaxess Technologies, Inc. was founded by Livio Valenti, Kathryn Kosuda, Michael Schrader in 2012.
- Who are Vaxess Technologies, Inc.'s investors?
- Vaxess Technologies, Inc.'s investors include Global Health Investment Corporation, Mission Biocapital, RA Capital.
- How much funding has Vaxess Technologies, Inc. raised?
- Vaxess Technologies, Inc. has disclosed $136.9M raised across 10 rounds.
- Where is Vaxess Technologies, Inc. headquartered?
- Vaxess Technologies, Inc. is headquartered in Cambridge, US.